NEW YORK--(BUSINESS WIRE)--Today, Celmatix, a next-generation women’s health company, announced it has been awarded $4.5 million from Empire State Development’s New York City Regional Economic Development Council (REDC) to expand its headquarters in Manhattan. This award represents the council’s largest life science investment in New York City this year.
Ten regional councils were established in 2011 to empower community, business, and academic leaders in each region of New York State to create community-based and performance-driven economic development. This year, the REDC announced more than $755 million in total economic and community development funding through this initiative, with $64.8 million awarded to 121 projects in New York City.
For Celmatix, this recognition follows a year of significant milestones for the company, including its announcement of the Fertilome® genetic test, which recently became the first multigene panel test for female reproductive conditions to be approved by the New York State Department of Health.
“Celmatix is truly a home-grown success story. I was originally drawn to New York City as a graduate student because there is no greater place to learn and innovate. Not only is there a large and thriving scientific community, but the energy here is like no other place on earth,” said Piraye Yurttas Beim, PhD, Founder and CEO of Celmatix. “As an entrepreneur, I chose to build my business here for the same reasons. New York State has been there for Celmatix every step of the way as we’ve transitioned from ambitious startup to innovative next generation women’s health company. From the training I received through New York State’s Center for Biotechnology program at Stony Brook University, to the support we received from the Empire State Development START-UP New York program when it was time to build our first lab, and now, with this award as we prepare to take the next step in the evolution of our company, we are honored to have continued support to grow and thrive in New York.”
Founded in 2009, Celmatix uses data and genetic insights to empower women and their physicians to make more informed, proactive, and personalized reproductive health decisions. Its offerings include Polaris®, a web-based data analytics platform that helps optimize patient management and counseling, and the recently launched Fertilome test, the world’s first multi-gene genetic test for reproductive health.
For more about Celmatix or to view available positions at the company, please visit www.celmatix.com/careers.
About Celmatix Inc.
Celmatix is a next-generation women’s health company transforming reproductive health care through genomics and big data. Founded in 2009 and based in New York City, Celmatix is disrupting how women approach their lifelong fertility journey by empowering them and their physicians with more personalized information. The company’s research-driven products include the Fertilome® test, the world’s first multigene panel test that reveals what a woman’s DNA says about her reproductive health, and Polaris®, a real-time predictive analytics platform in use at leading fertility clinics across the U.S., which helps physicians optimize patient outcomes and improve the patient experience.
